Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Brescia – page 19

554 clinical trials in Brescia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Brescia at a glance
554
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

554 trials in Brescia

Open in trial search

Breast cancer

Not yet recruiting

Premedication with dexamethasone to prevent interstitial lung disease in breast cancer patients receiving trastuzumab deruxtecan

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Parkinson's disease

Not yet recruiting

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Hepatocellular carcinoma+5

Not yet recruiting

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:Dualitybio Inc.

Graft versus host disease

Not yet recruiting

A study to evaluate the effectiveness of MC0518 (mesenchymal stromal cells) in adults with acute graft-versus-host disease that has not responded to steroids and ruxolitinib

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mesenchymal Stromal Cells, Ex Vivo Cultured
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo

Non-small cell lung cancer

Not yet recruiting

Study of cemiplimab with or without chemotherapy for non-small cell lung cancer patients with high PD-L1 levels to reduce rapid disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universita' Vita-salute S. Raffaele

Cervix carcinoma

Not yet recruiting

Study of cemiplimab with chemoradiotherapy for patients with locally advanced cervical cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cemiplimab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

West Nile viral infection

Not yet recruiting

A Study of Doravirine for Early Treatment of West Nile Virus Infection in Patients at Risk of Disease Worsening

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Asthma

Not yet recruiting

Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Salmeterol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Brescia

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer, chronic myeloid leukemia, and renal cell carcinoma. Studies evaluate novel combination therapies and treatment strategies for advanced cancer cases.

  • Colorectal Cancer Treatment
  • Leukemia Therapies
  • Advanced Renal Cancer

Research includes evaluation of targeted therapies and immunotherapy approaches.

02 Neurological Disorders

Comprehensive studies addressing Parkinson's disease, Frontotemporal Dementia, and Alzheimer's-related psychosis. Research focuses on novel therapeutic approaches and disease-modifying treatments.

  • Early-Stage Parkinson's Treatment
  • Dementia Management
  • Neurological Drug Development

Trials aim to improve patient outcomes and quality of life.

03 Autoimmune Conditions

Groundbreaking research in Psoriatic Arthritis, Crohn's Disease, and Sjögren's Syndrome. Studies evaluate biological therapies and innovative treatment approaches.

  • Inflammatory Disease Management
  • Autoimmune Response Modulation
  • Novel Therapeutic Approaches

Focus on developing targeted treatments for chronic conditions.

04 Cardiovascular Research

Studies addressing heart failure prevention and cardiovascular disease. Research evaluates new combination therapies and preventive approaches.

  • Heart Failure Prevention
  • Cardiovascular Risk Reduction
  • Therapeutic Combinations

Emphasis on preventive strategies and innovative treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.